A Phase 1, Randomized, Crossover, Open-label, 4 Period Study In Healthy Volunteers To Demonstrate The Lack Of Effect Of Rabeprazole And Food On The Pharmacokinetics Of PF-06463922 And To Assess The Relative Bioavailability Of Oral Solution To The Tablet Formulation Of PF-06463922

Trial Profile

A Phase 1, Randomized, Crossover, Open-label, 4 Period Study In Healthy Volunteers To Demonstrate The Lack Of Effect Of Rabeprazole And Food On The Pharmacokinetics Of PF-06463922 And To Assess The Relative Bioavailability Of Oral Solution To The Tablet Formulation Of PF-06463922

Completed
Phase of Trial: Phase I

Latest Information Update: 20 May 2016

At a glance

  • Drugs Lorlatinib (Primary) ; Lorlatinib (Primary) ; Rabeprazole
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 11 May 2016 Status changed from recruiting to completed.
    • 04 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
    • 04 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top